Cote; Aaron S.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Cote; Aaron S..The latest application filed is for "crystalline polymorphic forms of an antidiabetic compound".

Company Profile

0.13.12

Cote; Aaron S. - West Windsor NJ
Cote; Aaron S. - New Jersey NJ
Cote; Aaron S. - Rahway NJ
Cote; Aaron S. - West Windosr NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Crystalline polymorphic forms of an antidiabetic compound Grant 9,272,999 - Chung , et al. March 1, 2	2016-03-01
Crystalline Polymorphic Forms Of An Antidiabetic Compound App 20150197490 - Chung; John Y. L. ; et al.	2015-07-16
Crystalline polymorphic forms of an antidiabetic compound Grant 9,012,488 - Chung , et al. April 21, 2	2015-04-21
Preparation of lamivudine form I Grant 8,796,452 - Cohen , et al. August 5, 2	2014-08-05
Crystalline Polymorphic Forms Of An Antidiabetic Compound App 20140171480 - Chung; John Y. L. ; et al.	2014-06-19
Crystalline polymorphic forms of an antidiabetic compound Grant 8,697,740 - Chung , et al. April 15, 2	2014-04-15
Formulations of suberoylanilide hydroxamic acid and methods for producing same Grant 8,450,372 - Wong , et al. May 28, 2	2013-05-28
Preparation of Lamivudine Form I App 20120316339 - Cohen; Benjamin ; et al.	2012-12-13
Formulations of suberoylanilide hydroxamic acid and methods for producing same Grant 8,288,440 - Wong , et al. October 16, 2	2012-10-16
Process for the production of a crystalline glucagon receptor antagonist compound Grant 8,232,413 - Cohen , et al. July 31, 2	2012-07-31
Crystalline Polymorphic Forms Of An Antidiabetic Compound App 20120010262 - Chung; John Y.L. ; et al.	2012-01-12
Formulations of suberoylanilide hydroxamic acid and methods for producing the same Grant 8,093,295 - Wong , et al. January 10, 2	2012-01-10
Process for synthesizing a CETP inhibitor Grant 7,863,307 - Miller , et al. January 4, 2	2011-01-04
Process For The Production Of A Crystalline Glucagon Receptor Antagonist Compound App 20100184995 - Cohen; Benjamin M. ; et al.	2010-07-22
Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same App 20100119596 - Wong; Jeannie Chow ; et al.	2010-05-13
Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same App 20100112046 - Wong; Jeannie Chow ; et al.	2010-05-06
Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same App 20100113829 - Cote; Aaron S. ; et al.	2010-05-06
Process For Synthesizing A CETP Inhibitor App 20100041724 - Miller; Ross A. ; et al.	2010-02-18
Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use App 20090087492 - Johnson; Brian K. ; et al.	2009-04-02
Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same App 20080132575 - Wong; Jeannie Chow ; et al.	2008-06-05
Polymorphs of an androgen receptor modulator Grant 7,365,202 - Tan , et al. April 29, 2	2008-04-29
Polymorphs of an androgen receptor modulator App 20070129548 - Tan; Lushi ; et al.	2007-06-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.